While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

LCGC International interviewed Bob Pirok from the University of Amsterdam, Netherlands to discuss strategies for enhancing ...